cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenți antineoplazici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
ranolip 20 mg
ranbaxy (u.k.) limited - lisinoprilum - compr. - 20mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
ranolip 10 mg
ranbaxy (u.k.) limited - lisinoprilum - compr. - 10mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
ranolip 5 mg
ranbaxy (u.k.) limited - lisinoprilum - compr. - 5mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
lisinopril-bp 10 mg comprimate
sc balkan pharmaceuticals srl - lisinoprilum - comprimate - 10 mg
lisinopril-bp 20 mg comprimate
sc balkan pharmaceuticals srl - lisinoprilum - comprimate - 20 mg
lisinopril-bp 5 mg comprimate
sc balkan pharmaceuticals srl - lisinoprilum - comprimate - 5 mg
ranolip 10 mg
terapia s.a. - romania - lisinoprilum - compr. - 10mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
ranolip 20 mg
terapia s.a. - romania - lisinoprilum - compr. - 20mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei
ranolip 5 mg
terapia s.a. - romania - lisinoprilum - compr. - 5mg - inhibitori ai enzimei de conversie a angiotensinei inhibitori ai enzimei de conversie a angiotensinei